Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study.
Henderson A, Paterson DL, Chatfield MD, Tambyah PA, Lye DC, De PP, Lin RTP, Chew KL, Yin M, Lee TH, Yilmaz M, Cakmak R, Alenazi TH, Arabi YM, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj SS, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke DFM, Runnegar NJ, Miyakis S, Walls G, Khamis MAI, Zikri A, Crowe A, Ingram PR, Daneman N, Griffin P, Athan E, Roberts L, Beatson SA, Peleg AY, Cottrell K, Bauer MJ, Tan E, Chaw K, Nimmo GR, Harris-Brown T, Harris PNA; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Henderson A, et al. Among authors: griffin p. Clin Infect Dis. 2021 Dec 6;73(11):e3842-e3850. doi: 10.1093/cid/ciaa1479. Clin Infect Dis. 2021. PMID: 33106863 Clinical Trial.
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Harris PNA, et al. Among authors: griffin p. JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. JAMA. 2018. PMID: 30208454 Free PMC article. Clinical Trial.
Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia.
Pasay CJ, Rockett R, Sekuloski S, Griffin P, Marquart L, Peatey C, Wang CY, O'Rourke P, Elliott S, Baker M, Möhrle JJ, McCarthy JS. Pasay CJ, et al. Among authors: griffin p. J Infect Dis. 2016 Jul 1;214(1):105-13. doi: 10.1093/infdis/jiw128. Epub 2016 Apr 7. J Infect Dis. 2016. PMID: 27056954 Free PMC article. Clinical Trial.
MALDI-TOF MS meets WGS in a VRE outbreak investigation.
Schlebusch S, Price GR, Gallagher RL, Horton-Szar V, Elbourne LD, Griffin P, Venter DJ, Jensen SO, Van Hal SJ. Schlebusch S, et al. Among authors: griffin p. Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):495-499. doi: 10.1007/s10096-016-2824-4. Epub 2016 Nov 26. Eur J Clin Microbiol Infect Dis. 2017. PMID: 27889877
The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.
Denholm JT, Davis J, Paterson D, Roberts J, Morpeth S, Snelling T, Zentner D, Rees M, O'Sullivan M, Price D, Bowen A, Tong SYC; ASCOT Investigator Group. Denholm JT, et al. Trials. 2020 Jul 14;21(1):646. doi: 10.1186/s13063-020-04576-9. Trials. 2020. PMID: 32665040 Free PMC article.
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ, Mordant FL, Li Z, Wijesundara DK, Ellenberg P, Lackenby JA, Cheung STM, Modhiran N, Avumegah MS, Henderson CL, Hoger K, Griffin P, Bennet J, Hensen L, Zhang W, Nguyen THO, Marrero-Hernandez S, Selva KJ, Chung AW, Tran MH, Tapley P, Barnes J, Reading PC, Nicholson S, Corby S, Holgate T, Wines BD, Hogarth PM, Kedzierska K, Purcell DFJ, Ranasinghe C, Subbarao K, Watterson D, Young PR, Munro TP. Chappell KJ, et al. Among authors: griffin p. Lancet Infect Dis. 2021 Oct;21(10):1383-1394. doi: 10.1016/S1473-3099(21)00200-0. Epub 2021 Apr 19. Lancet Infect Dis. 2021. PMID: 33887208 Free PMC article. Clinical Trial.
Delusions of disseminated fungosis.
Gassiep I, Griffin PM. Gassiep I, et al. Case Rep Infect Dis. 2014;2014:458028. doi: 10.1155/2014/458028. Epub 2014 Dec 25. Case Rep Infect Dis. 2014. PMID: 25610675 Free PMC article.
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.
Playford EG, Munro T, Mahler SM, Elliott S, Gerometta M, Hoger KL, Jones ML, Griffin P, Lynch KD, Carroll H, El Saadi D, Gilmour ME, Hughes B, Hughes K, Huang E, de Bakker C, Klein R, Scher MG, Smith IL, Wang LF, Lambert SB, Dimitrov DS, Gray PP, Broder CC. Playford EG, et al. Among authors: griffin p. Lancet Infect Dis. 2020 Apr;20(4):445-454. doi: 10.1016/S1473-3099(19)30634-6. Epub 2020 Feb 3. Lancet Infect Dis. 2020. PMID: 32027842 Clinical Trial.
1,215 results